Table 1.

Demographics of patients with rheumatoid arthritis and healthy controls

	RA patients		Healthy controls
	Responders	Nonresponders
Participants, n	6	7	6
Gender F/M, n	6/0	7/0	6/0
Age, y	63 ± 2	65 ± 14	57 ± 10
Disease duration, y	17 ± 8	28 ± 16	n.a.
DAS28*	2.0 ± 0.7	3.8 ± 0.6	n.a.
RF-positive, n (%)	3 (50%)	6 (86%)	0 (0%)
ACPA-positive, n	4 (67%)	4 (57%)	0/6
MTX, mg/wk†	14 ± 5.18	16 ± 6.10	n.a.
Infliximab total, mg	8,367 ± 4,234	8,257 ± 7,051	n.a.

All RA patients received infliximab injection i.v. at a dose of 200 mg every 8 wk. DAS28, 28 joint disease activity score. RF, rheumatoid factor. ACPA, anticitrullinated protein antibodies. MTX, methotrexate. n.a., not applicable.

^*P = 0.0005 between responders and nonresponders (Student’s unpaired, two-tailed, heteroscedastic test).

^†One patient was treated with mycophenolate mofetil instead of MTX.